Diabetes Mellitus, Type 2

27 competing products in clinical development for Diabetes Mellitus, Type 2.

Pipeline by Phase

Pre-clinical2

Phase 16

Phase 21

Phase 2/31

Phase 312

Approved5

All Products (27)

Product	Company	Stage	Status	Hype
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)	Eli Lilly	Approved	Completed	85
Lispro	Eli Lilly	Approved	Completed	85
premeal insulin lispro mixtures + insulin glargine + metformin	Eli Lilly	Approved	Completed	85
Pioglitazone + Alogliptin + Alogliptin + Metformin + Dapagliflozin	Celltrion	Approved	Completed	85
AC2993	Eli Lilly	Phase 3	Completed	77
Insulin Lispro Protamine Suspension + Insulin Glargine	Eli Lilly	Phase 3	Completed	77
Placebo + Linagliptin	Eli Lilly	Phase 3	Completed	77
Retatrutide + Semaglutide	Eli Lilly	Phase 3	Active	77
Linagliptin + Empagliflozin placebo + linagliptin placebo low dose + Empagliflozin + linagliptin low dose + Linagliptin placebo + Empagliflozin + linagliptin high dose + Empa + lina highdose placebo	Eli Lilly	Phase 3	Completed	77
Toujeo	MIRA Pharmaceuticals	Approved	Completed	77
Placebo + BI 10773 + Placebo + BI 10773 + Placebo + Placebo	Eli Lilly	Phase 3	Completed	77
Empagliflozin + Placebo + Sitagliptin + Placebo	Eli Lilly	Phase 3	Withdrawn	77
placebo + linagliptin + background therapy	Eli Lilly	Phase 3	Completed	77
LY2189265 + Exenatide + Placebo + Metformin + Pioglitazone	Eli Lilly	Phase 3	Completed	77
GP40081 + NovoMix 30	GEROPHARM	Phase 3	UNKNOWN	69
Humalog Mix25 + Insulin Lispro Biphasic 25	GEROPHARM	Phase 3	Completed	69
Insulin Humulin® NPH + Insulin Rinsulin® NPH	GEROPHARM	Phase 3	Completed	69
Human Insulin Inhalation Powder + Neutral protamine hagedorn insulin	Eli Lilly	Phase 2/3	Completed	65
LY2428757 + Placebo	Eli Lilly	Phase 2	Completed	52
LY3209590 + Insulin Degludec	Eli Lilly	Phase 1	Completed	33
LY3209590 + Placebo	Eli Lilly	Phase 1	Completed	33
LY900014 (SC) + LY900014 (IV)	Eli Lilly	Phase 1	Completed	33
Placebo + LY2922470	Eli Lilly	Phase 1	Completed	33
Tirzepatide	Eli Lilly	Phase 1	Recruiting	33
Placebo + LY2922083	Eli Lilly	Phase 1	Completed	33
empagliflozin + DPP-4 inhibitors	Eli Lilly	Pre-clinical	Completed	23
Empagliflozin + DPP-4 inhibitor + GLP-1 receptor agonist	Eli Lilly	Pre-clinical	Active	23